Takeda Pharmaceutical (TAK) Financial Analysis & Valuation | Quarter Chart
Takeda Pharmaceutical (TAK)
TAKPrice: $15.98
Fair Value: 🔒
🔒score
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of ga... more
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, ... more
Description
Shares
| Market Cap | $50.49B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | JP | CEO | Christophe Weber |
| IPO Date | 2010-01-05 | CAGR | 0.07% |
| Employees | 49,281 | Website | www.takeda.com |
| Div. Yield | 4.05% | Payout Ratio | 1.63% |
| Buy Back Yield | 99.3% | Total Yield | 103.35% |
TAK chart loading...
Fundamentals
Technicals
| Enterprise Value | $13489.88B | P/E Ratio | 9.29 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1.73 | P/B Ratio | 0.99 |
| P/CF Ratio | 7.95 | P/FCF Ratio | 9.98 |
| EPS | $1.72 | EPS Growth 1Y | 80.51% |
| EPS Growth 3Y | -40.28% | EPS Growth 5Y | -49.47% |
| Revenue Growth 1Y | -0.75% | Gross Margin | 0.59% |
| Operating Margin | 0.11% | Profit Margin | 0.04% |
| ROE | 0.03% | ROA | 0.01% |
| ROCE | 0.04% | Current Ratio | 1.27 |
| Quick Ratio | 0.7 | Cash Ratio | 0.24 |
| Debt/Equity | 0.63 | Interest Coverage | 1.33 |
| Altman Z Score | 1.22 | Piotroski Score | 7 |